Effects of the aminopeptidase P inhibitor apstatin on bradykinin-induced inositol 1,4,5-triphosphate in neonatal rat cardiomyocytes.
We investigated the effect of apstatin (an aminopeptidase P inhibitor) on bradykinin-induced inositol 1,4,5-triphosphate (IP3) formation and glucose uptake in isolated neonatal rat cardiomyocytes. Apstatin enhanced bradykinin-induced IP3 formation in a dose-dependent manner. We found that 1 microM Hoe 140 (a bradykinin B2-receptor antagonist) significantly decreased the potentiation of bradykinin-induced IP3 production by 5 microM apstatin from 781.8+/-67.2 to 127.4+/-33.0 pmol/mg protein; 5 microM apstatin increased bradykinin-induced glucose uptake from 197.0+/-25.5 to 297.3+/-64.0 pmol/h per milligram of protein. The stimulation of glucose uptake with apstatin was blocked to 132.5+/-26.2 pmol/h per milligram of protein by 1 microM Hoe 140. We conclude that apstatin stimulates bradykinin-induced IP3 formation and glucose uptake by preventing the degradation of bradykinin.